Decreased toll-interacting protein and peroxisome proliferator-activated receptor γ are associated with increased expression of toll-like receptors in colon carcinogenesis

Journal of Clinical Pathology

Volumn 65, Issue 4, 2012, Pages 302-308

  Pimentel Nunes, Pedro ^a,b   Gonçalves, Nádia ^a   Boal Carvalho, Inês ^a   Afonso, Luís ^b   Lopes, Paula ^b   Roncon Albuquerque Jr , Roberto ^a   Soares, João Bruno ^a   Cardoso, Elisabete ^b   Henrique, Rui ^b   Moreira Dias, Luís ^b   Dinis Ribeiro, Mário ^a,b   Leite Moreira, Adelino F ^a  

^a University of Porto   (Portugal)

^b PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; I KAPPA B; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA;

ADENOMA; ADULT; ARTICLE; CANCER GRADING; CANCER GROWTH; CLINICAL ARTICLE; COLON BIOPSY; COLON CARCINOGENESIS; COLON MUCOSA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; CROSS-SECTIONAL STUDIES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NF-KAPPA B; PPAR GAMMA; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84858698790     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200567     Document Type: Article

References (67)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
4. Ahnen DJ. The American College of Gastroenterology Emily Couric Lecture - the adenoma-carcinoma sequence revisited: has the era of genetic tailoring finally arrived? Am J Gastroenterol 2011;106:190-8.
5. Noffsinger AE. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol 2009;4:343-64.
6. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8. (Pubitemid 24294584)
7. Sarraf P, Mueller E, Smith WM, et al. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 1999;3:799-804. (Pubitemid 29323058)
8. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99:2254-9. (Pubitemid 27203783)
9. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511. (Pubitemid 38931765)
10. Kawai T, Akira S. TLR signaling. Cell Death Differ 2006;13:816-25.
11. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003;85:85-95. (Pubitemid 36071561)
12. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-76. (Pubitemid 37174535)
13. Kaisho T, Akira S. Pleiotropic function of Toll-like receptors. Microbes Infect 2004;6:1388-94. (Pubitemid 41110582)
14. Fukata M, Chen A, Klepper A, et al. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology 2006;131:862-77. (Pubitemid 44316821)
15. Chang YJ, Wu MS, Lin JT, et al. Helicobacter pylori-induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. J Immunol 2005;175:8242-52.
16. Spitzer JA, Zheng M, Kolls JK, et al. Ethanol and LPS modulate NF-kappaB activation, inducible NO synthase and COX-2 gene expression in rat liver cells in vivo. Front Biosci 2002;7:a99-108.
17. Lee IT, Lee CW, Tung WH, et al. Cooperation of TLR2 with MyD88, PI3K, and Rac1 in lipoteichoic acid-induced cPLA2/COX-2-dependent airway inflammatory responses. Am J Pathol 2010;176:1671-84.
18. Desreumaux P, Dubuquoy L, Nutten S, et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 2001;193:827-38. (Pubitemid 32524532)
19. Gupta RA, Polk DB, Krishna U, et al. Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappa B-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J Biol Chem 2001;276:31059-66.
20. Kelly D, Campbell JI, King TP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 2004;5:104-12. (Pubitemid 38081475)
21. Melmed G, Thomas LS, Lee N, et al. Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J Immunol 2003;170:1406-15. (Pubitemid 36139508)
22. Otte JM, Cario E, Podolsky DK. Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology 2004;126:1054-70. (Pubitemid 38451177)
23. Pimentel-Nunes P, Soares JB, Roncon-Albuquerque R Jr, et al. Toll-like receptors as therapeutic targets in gastrointestinal diseases. Expert Opin Ther Targets 2010;14:347-68.
24. Hopkins PA, Sriskandan S. Mammalian Toll-like receptors: to immunity and beyond. Clin Exp Immunol 2005;140:395-407. (Pubitemid 40813950)
25. Liew FY, Xu D, Brint EK, et al. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005;5:446-58. (Pubitemid 40835033)
26. Ortega-Cava CF, Ishihara S, Rumi MA, et al. Strategic compartmentalization of Toll-like receptor 4 in the mouse gut. J Immunol 2003;170:3977-85. (Pubitemid 36428158)
27. Abreu MT, Thomas LS, Arnold ET, et al. TLR signaling at the intestinal epithelial interface. J Endotoxin Res 2003;9:322-30.
28. Abreu MT, Vora P, Faure E, et al. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 2001;167:1609-16. (Pubitemid 32703162)
29. Furrie E, Macfarlane S, Thomson G, et al. Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology 2005;115:565-74. (Pubitemid 41032444)
30. Chuang TH, Ulevitch RJ. Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors. Nat Immunol 2004;5:495-502. (Pubitemid 38660461)
31. Mansell A, Smith R, Doyle SL, et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol 2006;7:148-55. (Pubitemid 43135880)
32. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323:1228-33. (Pubitemid 20366527)
33. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451-9. (Pubitemid 38182302)
34. Uronis JM, Muhlbauer M, Herfarth HH, et al. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One 2009;4:e6026.
35. Fukata M, Chen A, Vamadevan AS, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007;133:1869-81.
36. Laqueur GL, Matsumoto H, Yamamoto RS. Comparison of the carcinogenicity of methylazoxymethanol-beta-D-glucosiduronic acid in conventional and germfree Sprague - Dawley rats. J Natl Cancer Inst 1981;67:1053-5. (Pubitemid 12252092)
37. Swidsinski A, Khilkin M, Kerjaschki D, et al. Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology 1998;115:281-6. (Pubitemid 28363420)
38. Doan HQ, Bowen KA, Jackson LA, et al. Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells. Anticancer Res 2009;29:2473-8.
39. Yoshioka T, Morimoto Y, Iwagaki H, et al. Bacterial lipopolysaccharide induces transforming growth factor beta and hepatocyte growth factor through toll-like receptor 2 in cultured human colon cancer cells. J Int Med Res 2001;29:409-20. (Pubitemid 33061660)
40. Pimentel-Nunes P, Roncon-Albuquerque R Jr, Goncalves N, et al. Attenuation of toll-like receptor 2-mediated innate immune response in patients with alcoholic chronic liver disease. Liver Int 2010;30:1003-11.
41. Pimentel-Nunes P, Afonso L, Lopes P, et al. Increased expression of toll-like receptors (TLR) 2, 4 and 5 in gastric dysplasia. Pathol Oncol Res 2011;17:677-83.
42. Giovannucci E, Ascherio A, Rimm EB, et al. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 1995;122:327-34.
43. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005;97:1679-87. (Pubitemid 41672234)
44. Arber N, Spicak J, Racz I, et al. Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial. Am J Gastroenterol 2011;106:1135-46.
45. Beutler BA. TLRs and innate immunity. Blood 2009;113:1399-407.
46. Fischer M, Ehlers M. Toll-like receptors in autoimmunity. Ann NY Acad Sci 2008;1143:21-34.
47. Fukata M, Abreu MT. Role of Toll-like receptors in gastrointestinal malignancies. Oncogene 2008;27:234-43.
48. Kluwe J, Mencin A, Schwabe RF. Toll-like receptors, wound healing, and carcinogenesis. J Mol Med 2009;87:125-38.
49. Pasare C, Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 2005;438:364-8. (Pubitemid 41643953)
50. Fukata M, Abreu MT. Pathogen recognition receptors, cancer and inflammation in the gut. Curr Opin Pharmacol 2009;9:680-7.
51. Earl TM, Nicoud IB, Pierce JM, et al. Silencing of TLR4 decreases liver tumor burden in a murine model of colorectal metastasis and hepatic steatosis. Ann Surg Oncol 2009;16:1043-50.
52. Huang B, Zhao J, Li H, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005;65:5009-14. (Pubitemid 40827306)
53. Nihon-Yanagi Y, Terai K, Murano T, et al. Tissue expression of Toll-like receptors 2 and 4 in sporadic human colorectal cancer. Cancer Immunol Immunother 2012;61(1):71-7.
54. Cammarota R, Bertolini V, Pennesi G, et al. The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J Transl Med 2010;8:112.
55. Wang EL, Qian ZR, Nakasono M, et al. High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer 2010;102:908-15.
56. Boraska Jelavic T, Barisic M, Drmic Hofman I, et al. Microsatelite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer. Clin Genet 2006;70:156-60. (Pubitemid 44028102)
57. Bulut Y, Faure E, Thomas L, et al. Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. J Immunol 2001;167:987-94. (Pubitemid 32660856)
58. Burns K, Clatworthy J, Martin L, et al. Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat Cell Biol 2000;2:346-51.
59. Didierlaurent A, Brissoni B, Velin D, et al. Tollip regulates proinflammatory responses to interleukin-1 and lipopolysaccharide. Mol Cell Biol 2006;26:735-42. (Pubitemid 43146471)
60. Li T, Hu J, Li L. Characterization of Tollip protein upon lipopolysaccharide challenge. Mol Immunol 2004;41:85-92. (Pubitemid 38609400)
61. Zhang G, Ghosh S. Negative regulation of toll-like receptor-mediated signaling by Tollip. J Biol Chem 2002;277:7059-65. (Pubitemid 34953094)
62. Brissoni B, Agostini L, Kropf M, et al. Intracellular trafficking of interleukin-1 receptor I requires Tollip. Curr Biol 2006;16:2265-70. (Pubitemid 44739284)
63. Katoh Y, Imakagura H, Futatsumori M, et al. Recruitment of clathrin onto endosomes by the Tom1-Tollip complex. Biochem Biophys Res Commun 2006;341:143-9. (Pubitemid 43117398)
64. Katoh Y, Shiba Y, Mitsuhashi H, et al. Tollip and Tom1 form a complex and recruit ubiquitin-conjugated proteins onto early endosomes. J Biol Chem 2004;279:24435-43. (Pubitemid 38725307)
65. Conterno L, Fava F, Viola R, et al. Obesity and the gut microbiota: does up-regulating colonic fermentation protect against obesity and metabolic disease? Genes Nutr 2011;6:241-60.
66. Greer JB, O'Keefe SJ. Microbial induction of immunity, inflammation, and cancer. Front Physiol 2011;1:168.
67. Zhu Y, Michelle Luo T, Jobin C, et al. Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett 2011;309:119-27.